Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

FRANCE: French Study Indicates Some Patients Can Control HIV After Stopping Treatment




 

New York Times (03.15.13)

Fourteen adults who started antiretroviral therapy (ART) soon after becoming HIV-infected and continued treatment for at least a year have been able to control the virus for one to seven years, even after stopping ART, according to French researchers. Lead author Asier Sáez-Cirión called the success a “functional cure” in which the virus is still present in low levels; most of the patients had undetectable HIV blood levels (below 50 copies per milliliter), but some had up to a few hundred copies per milliliter. Sáez-Cirión described the study patients as “post-treatment controllers” in contrast to “elite controllers” who comprise the less than one percent of HIV-infected people whose bodies are able to control HIV without antiviral drugs. The study indicates that the post-treatment controllers developed high viral loads shortly after infection, which led to starting drug treatment within several months of infection. Post-treatment controllers also have smaller viral reservoirs and a smaller proportion of long-lived immune cells. Elite controllers are able to keep virus levels down, even at the start of infection. The study did not provide enough information to identify HIV-infected people who could safely stop ART. Dr. Douglas D. Richman, director of the Center for AIDS Research at the University of California – San Diego, emphasized that it is difficult to identify newly infected patients and start treatment in a timely way. Dr. Max Essex, of the Harvard School of Public Health AIDS Initiative, stated that current tests for viral loads are so sensitive it might be possible to take patients off treatment for a month and restart ART if the viral loads go up sharply. The full report, “Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study,” was published online in the journal PLOS Pathogens (2013; doi:10.1371/journal.ppat.1003211).



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in March 18, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.